Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.05
-$0.07-6.25%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -50.53M | -44.90M | -31.93M | -30.49M | -23.39M |
| Total Depreciation and Amortization | 151.00K | 144.00K | 112.00K | 103.00K | 108.00K |
| Total Amortization of Deferred Charges | 618.00K | 273.00K | 265.00K | 345.00K | 217.00K |
| Total Other Non-Cash Items | 285.00K | 3.82M | 3.42M | 3.27M | 2.65M |
| Change in Net Operating Assets | 7.85M | 2.56M | -3.47M | 5.21M | 975.00K |
| Cash from Operations | -41.62M | -38.12M | -31.61M | -21.57M | -19.44M |
| Capital Expenditure | -83.00K | -139.00K | -248.00K | -1.25M | -4.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.24M | -74.47M | 12.34M | 25.42M | -77.19M |
| Cash from Investing | -39.33M | -74.61M | 12.09M | 24.17M | -77.20M |
| Total Debt Issued | 1.00K | 49.96M | -- | 24.97M | -249.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 139.03M | -- | -- | 94.27M |
| Repurchase of Common Stock | -211.00K | 0.00 | -824.00K | -63.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -210.00K | 189.00M | -824.00K | 24.91M | 94.02M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.16M | 76.27M | -20.34M | 27.51M | -2.62M |